Renovorx announces late-breaking oral presentation at 2023 esmo world congress on gastrointestinal cancer

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the acceptance of a late-breaking oral presentation for its lead product candidate renovogem, in the treatment of locally advanced pancreatic cancer (lapc), at the upcoming esmo world congress on gastrointestinal cancer (esmo gi). the conference will be held june 28 – july 1, 2023, in barcelona, spa.
RNXT Ratings Summary
RNXT Quant Ranking